Latest news with #IndiviorPLC
Yahoo
a day ago
- Business
- Yahoo
Global Antidote Market to Cross the USD 4 Billion Mark by 2032
The antidote market is witnessing substantial growth, largely propelled by the growing incidence of poisoning, drug overdoses, and snake or animal bites. This rising demand is supported by greater public health awareness, government efforts to combat drug overdoses, and continuous progress in product innovation. Moreover, strategic product launches and technological advancements by key industry players in the treatment of toxicities are further accelerating the market's upward momentum. New York, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight The antidote market is witnessing substantial growth, largely propelled by the growing incidence of poisoning, drug overdoses, and snake or animal bites. This rising demand is supported by greater public health awareness, government efforts to combat drug overdoses, and continuous progress in product innovation. Moreover, strategic product launches and technological advancements by key industry players in the treatment of toxicities are further accelerating the market's upward momentum. DelveInsight's Antidote Market Insights report provides the current and forecast market analysis, individual leading antidote companies' market shares, challenges, antidote market drivers, barriers, trends, and key market antidote companies in the market. Key Takeaways from the Antidote Market Report As per DelveInsight estimates, North America is anticipated to dominate the global antidote market during the forecast period. In the antidote type segment of the antidote market, the biological antidotes category accounted for the largest market share in 2024. Notable antidote companies such as Pfizer Inc., SERB Pharmaceuticals, McKesson Corporation, Amneal Pharmaceuticals LLC, EMERGENT, Novartis AG, Troikaa, Hope Pharmaceuticals, Rare Disease Therapeutics, Inc., BTG International Inc., Viatris Inc., Glentham® Life Sciences Limited, Kaleo, Inc., SGPharma Pvt. Ltd., American Regent, Inc., FFF Enterprises, Inc., Amphastar Pharmaceuticals, Inc., Purdue Pharma L.P., Indivior PLC, Harm Reduction Therapeutics, Inc., and several others are currently operating in the antidote market. In August 2024, Purdue Pharma L.P. received FDA approval for the New Drug Application (NDA) of Zurnai™ (nalmefene injection) auto-injector. In March 2024, Indivior PLC announced the results of a pharmacodynamic study showcasing that OPVEE® effectively and rapidly reverses opioid-induced respiratory depression, the primary cause of death in opioid overdoses. This breakthrough demonstrates the potential of OPVEE® as a critical intervention in emergency overdose situations, offering a swift response to prevent life-threatening complications associated with opioid toxicity. To read more about the latest highlights related to the antidote market, get a snapshot of the key highlights entailed in the Global Antidote Market Report Antidote Overview Antidote refers to a substance that counteracts the harmful effects of a poison or toxin. When an individual is exposed to a toxic substance, whether through ingestion, inhalation, injection, or skin contact, an antidote can help neutralize the toxin, reverse its effects, or support the body's natural elimination processes. Antidotes work through various mechanisms: some bind directly to the toxin, others block its biological effects, and some enhance the body's own detoxification systems. Common examples include activated charcoal for many oral poisons, naloxone for opioid overdoses, and atropine for certain nerve agent or pesticide exposures. The development and timely administration of antidotes are crucial in emergency medicine and toxicology. While some antidotes are broadly effective against a wide range of toxins, others are highly specific, targeting a single compound or class of poisons. Due to the diversity of toxic agents and the complexity of their effects on human biology, ongoing research in pharmacology and biochemistry continues to play a critical role in discovering new antidotes. In mass exposure events or cases of rare poisoning, the availability and distribution of appropriate antidotes can be a matter of life and death, underscoring their significance in public health preparedness and clinical Market Insights North America held a substantial share of the antidote market in 2024, fueled by several critical factors. The growing number of poisoning and drug overdose incidents across the region has significantly increased the need for effective antidote solutions. In particular, the opioid epidemic in the United States has driven demand for treatments like naloxone, which can reverse opioid overdoses. Public health campaigns and government-led efforts to curb and manage drug overdoses have further enhanced access to antidotes. Moreover, the market is witnessing a boost from ongoing pharmaceutical innovation and the introduction of new, targeted treatments. In response to this concerning trend, regional authorities have launched various initiatives to address drug overdoses and poisoning. For example, the U.S. Food and Drug Administration (FDA) implemented the Overdose Prevention Framework, which aims to reduce unnecessary opioid prescriptions, encourage harm-reduction strategies through education and innovation, and support the development of evidence-based therapies for substance use disorders and overdoses. Canada is also actively combating the overdose crisis. The Canadian government is investing in prevention programs, expanding access to treatment and harm-reduction services, and leveraging data-driven approaches to guide policy-making. These comprehensive efforts are fostering an environment conducive to the growth of the antidote market across North America. Additionally, pharmaceutical companies in the region are intensifying research and development efforts to bring advanced overdose treatments to market. For instance, in August 2024, Purdue Pharma L.P. received FDA approval for its New Drug Application (NDA) for Zurnai™ (nalmefene injection) auto-injector. This product is designed for emergency use in opioid overdoses caused by both natural and synthetic opioids in adults and adolescents aged 12 and above. The approval of Zurnai™ has expanded the arsenal of available opioid overdose antidotes, offering a fast-acting, user-friendly option to help tackle the ongoing opioid crisis. To know more about why North America is leading the market growth in the antidote market, get a snapshot of the Antidote Market Outlook Antidote Market Dynamics The antidote market is a crucial segment of the global pharmaceutical and toxicology landscape, driven by the increasing incidence of poisoning cases from pharmaceuticals, snake bites, chemical exposure, and overdoses. With growing awareness about drug misuse and rising environmental hazards, the demand for antidotes has surged in both developed and developing countries. Additionally, the rise in hospital admissions due to opioid overdoses, especially in North America and parts of Europe, has directly increased the need for effective and rapid-response antidotes like naloxone. One of the primary market dynamics shaping the antidote sector is the regulatory landscape. Antidotes, often falling under emergency-use drugs, receive fast-track approvals in certain jurisdictions due to their life-saving potential. Governments and healthcare bodies have also begun stockpiling critical antidotes as part of national preparedness programs, especially in regions vulnerable to snake bites or chemical attacks. Furthermore, innovations in biotechnology have allowed the development of more targeted and efficient antidotes, including monoclonal antibodies and small molecule inhibitors tailored for specific toxins or venoms. However, the market faces significant challenges. Many antidotes are expensive to develop and maintain, especially when the target population is small or geographically limited. For example, antivenoms for rare snake species may not be commercially viable due to high R&D costs and limited demand. This has led to a reliance on public-private partnerships and NGO involvement to ensure production and distribution in low-income areas. Moreover, the shelf-life and storage requirements of many antidotes add to supply chain complexity, often limiting their availability in remote or underdeveloped regions. Looking ahead, the antidote market is expected to benefit from increased global focus on public health preparedness and bioterrorism defense. The COVID-19 pandemic underscored the importance of rapid medical response capabilities, prompting governments to revisit their emergency drug inventories. Additionally, as pharmaceutical companies invest in advanced drug delivery systems and synthetic biology, novel antidotes with longer shelf lives and broader efficacy profiles are likely to emerge. The integration of digital health tools and AI in toxicology response systems could also streamline the identification and administration of antidotes, improving patient outcomes and operational efficiency in emergency care. Get a sneak peek at the antidote market dynamics @ Antidote Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Antidote Market CAGR ~7% Antidote Market Size by 2032 USD 4 Billion Key Antidote Companies Pfizer Inc., SERB Pharmaceuticals, McKesson Corporation, Amneal Pharmaceuticals LLC, EMERGENT, Novartis AG, Troikaa, Hope Pharmaceuticals, Rare Disease Therapeutics, Inc., BTG International Inc., Viatris Inc., Glentham® Life Sciences Limited, Kaleo, Inc., SGPharma Pvt. Ltd., American Regent, Inc., FFF Enterprises, Inc., Amphastar Pharmaceuticals, Inc., Purdue Pharma L.P., Indivior PLC, Harm Reduction Therapeutics, Inc., among others Antidote Market Assessment Antidote Market Segmentation Antidote Market Segmentation By Type: Chemical Antidotes and Biological Antidotes Antidote Market Segmentation By Route of Administration: Oral and Parenteral Antidote Market Segmentation By Distribution Channel: Hospital and Retail Pharmacies Antidote Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the antidote market are set to emerge as the trendsetter explore @ Antidote Companies Table of Contents 1 Antidote Market Report Introduction 2 Antidote Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Antidote Market Key Factors Analysis 6 Antidote Market Porter's Five Forces Analysis 7 Antidote Market Layout 8 Antidote Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the antidote market by 2032? Click to get a snapshot of the Antidote Market Analysis Related Reports Heavy Metal Poisoning Market Heavy Metal Poisoning Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key heavy metal poisoning companies, including EmeraMed, Magellan Diagnostics, Bezoloven Inc., among others. Substance Use Disorder Market Substance Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SUD companies including BioXcel Therapeutics, NFL Biosciences, STALICLA, Embera NeuroTherapeutics, PleoPharma, Kinnov Therapeutics, Imbrium Therapeutics, Atai Life Sciences, Beckley Psytech, among others. Opioid Use Disorder Market Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key OUD companies including Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, among others. Cocaine Use Disorder Market Cocaine Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CUD companies including STALICLA, Embera NeuroTherapeutics, among others. Cocaine Intoxication Market Cocaine Intoxication Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cocaine intoxication companies including Tonix Pharmaceutical, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circular published by Indivior on May 3, 2024, the Board noted its intention to maintain the Company's secondary listing in London, "for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole." Following the completion of Indivior's transition to a U.S. primary listing, the Board has kept its listing structure under regular review. As part of such review, the Company has considered, among other things, the liquidity and trading volumes of Ordinary Shares on each of the Nasdaq Stock Market ("Nasdaq") and the LSE, the location of its shareholders, as well as the cost and administrative requirements related to its secondary listing in London. In further consideration of Indivior's listing structure, the Board now believes that the London Delisting will be beneficial for the following reasons: Fully aligns with Indivior's most attractive and valuable opportunity set – U.S. SUBLOCADE; Better reflects the Company's geographic net revenue profile; over 80% of net revenue is generated from the U.S.; Eliminates the cost and complexity of maintaining a secondary listing; Recognizes that liquidity on Nasdaq now far outweighs liquidity on the LSE; as of May 27th, trading on the Nasdaq now accounts for approximately 75% of total trading volume across both exchanges over the last 30 days; Takes account of the location of most holders of Ordinary Shares by value; over 70% are now held by shareholders located in the U.S.; and Permits timing of material news announcements that aligns with the Company's U.S. peer set. Accordingly, the Company hereby gives notice that it has requested that: (i) the FCA cancel the listing of the Ordinary Shares on the Equity Shares (Transition) category of the Official List of the FCA; and (ii) the LSE cancel the admission to trading of the Ordinary Shares on the main market for listed securities of the LSE. David Wheadon, Chair, said: "We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior's business. We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity." Process for and principal effects of the London Delisting In accordance with U.K. Listing Rule 21.2.17R, the Company is required to give at least 20 business days' notice of the London Delisting. To further accommodate shareholders of Indivior PLC, the Company is providing approximately 40 business days' notice of the London Delisting. As such, it is intended that the London Delisting will become effective from 8:00 a.m. (U.K. time) on July 25, 2025, such that the last day of trading of the Ordinary Shares on the LSE will be July 24, 2025. Following the London Delisting: (i) it will no longer be possible to trade Ordinary Shares on the LSE; and (ii) the Company will maintain its listing of its Ordinary Shares on Nasdaq. The London Delisting is expected to have no impact for shareholders who are direct holders of Ordinary Shares or who hold their interests in Ordinary Shares through their nominated DTC broker or custodian. Holders of U.K. issued Indivior Depositary Interests ("U.K. DIs") and participants in Indivior's Corporate Sponsored Nominee facility ("CSN") are strongly encouraged to read Appendix 1 to this announcement, which contains further details of the arrangements that will apply to them following the London Delisting and the actions that they may wish to take in advance of the London Delisting (including the steps and actions required to convert their interests into holdings of Ordinary Shares, directly or through a DTC broker or custodian, from which they can be traded directly on Nasdaq). As the Company is assigned to the Equity Shares (Transition) category of the Official List, no shareholder approval is required for the London Delisting. The Company has prepared an FAQ document for shareholders, which is available at Shareholder FAQ. Takeover Code The Takeover Code (the "Code") applies to any company which has its registered office in the U.K., the Channel Islands or the Isle of Man if any of its equity share capital or other transferable securities carrying voting rights are admitted to trading on a U.K. regulated market, a U.K. Multilateral Trading Facility ("MTF"), or a stock exchange in the Channel Islands or the Isle of Man. The Code therefore currently applies to the Company as its Ordinary Shares are admitted to trading on the LSE, which is a U.K. regulated market. The Code also applies to any company which has its registered office in the U.K., the Channel Islands or the Isle of Man if any of its securities were admitted to trading on a U.K. regulated market, a U.K. MTF, or a stock exchange in the Channel Islands or the Isle of Man at any time during the preceding two years. Accordingly, if the London Delisting becomes effective, the Code will continue to apply to the Company for a period of two years after the London Delisting, following which the Code will cease to apply to the Company. While the Code continues to apply to the Company, a mandatory cash offer will be required to be made if either: (a) any person acquires an interest in Ordinary Shares which (taken together with the Ordinary Shares in which the person or any person acting in concert with that person is interested) carry 30% or more of the voting rights of the Company; or (b) any person, together with persons acting in concert with that person, is interested in Ordinary Shares which in the aggregate carry not less than 30% of the voting rights of a Company but does not hold Ordinary Shares carrying more than 50% of such voting rights and such person, or any person acting in concert with that person, acquires an interest in any other Ordinary Shares which increases the percentage of Ordinary Shares carrying voting rights in which that person is interested. Brief details of the Takeover Panel (the "Panel"), and of the protections afforded by the Code, are set out in Appendix 2 to this announcement. Important Cautionary Note Regarding Forward-looking Statements Certain statements contained herein are forward-looking statements." Forward-looking statements include, among other things, express and implied statements pertaining to (i) our intentions with respect to the London Delisting and our expectation that it will become effective; (ii) expected future sources of shareholder value, (iii) expected benefits of the London Delisting, (iv) estimates of costs and complexity of maintaining a secondary listing, and (v) statements containing the words "believe", "anticipate", "plan", "expect", "intend", "estimate", "forecast," "strategy", "target", "guidance", "outlook", "potential", "project", "priority," "may", "will", "should", "would", "could", "can", "outlook," the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. For information about some of the risks and important factors that could affect our future results and financial condition, see the discussion of "Risk Factors" in our Annual Report on Form 10-K filed March 3, 2025, Part II Item 1A herein, our Form 10-Q filed May 1, 2025, and our other filings with the U.S. Securities and Exchange Commission. We have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting This announcement is being made by Alice Givens, Company Secretary. Appendix 1: Additional Details for Holders of U.K. DIs and CSN participants Holders of U.K. DIs and CSN participants are advised to read this Appendix carefully to ensure that they understand the arrangements that will apply to them following the London Delisting and the actions that they may wish to take in advance of the London Delisting. If in doubt as to the action they should take, they are recommended to seek advice from their qualified financial advisor. U.K. DI Holders The Company's existing U.K. DI arrangements will not be impacted by the London Delisting. Accordingly, following the London Delisting, shareholders may continue to hold their interests in Ordinary Shares in the form of U.K. DIs, that is through CREST. However, following the London Delisting it will only be possible to place on market trades in respect of Ordinary Shares on Nasdaq. Consequently, in order to trade their Ordinary Shares following the London Delisting, U.K. DI holders will have to reposition their interests in Ordinary Shares into a DTC broker or custodian account by: (i) cancelling their U.K. DIs through the delivery of a cross-border instruction in respect of the underlying Ordinary Shares through CREST to Computershare Investor Services PLC ("Computershare U.K.", as the issuer of the U.K. DIs) in the form of a CREST stock withdrawal message (CREST system message type: STW); and (ii) instructing Computershare U.K. to deliver their interests in Ordinary Shares into the account of their chosen bank, broker, custodian firm, financial institution and/or other person that is a participant in DTC (a "DTC Participant"). The cancellation of U.K. DIs is subject to a charge, depending on the value of the underlying Ordinary Shares. The minimum cancellation charge is currently $125. For general enquiries, details of the current cancelation charges or for assistance in cancelling U.K. DIs and lodging cross- border instructions, holders, or brokers, of U.K. DIs should contact Computershare U.K. by phone on +44 (0) 370-707-1820 (from inside or outside the U.K.). Lines are open 8:30 a.m. to 5:30 p.m. (U.K. time), Monday to Friday (excluding public holidays in England and Wales). If you hold your U.K. DIs through a broker, custodian or nominee (for example you are an investor through a retail nominee arrangement and are not a CREST participant directly), please contact your broker, custodian or nominee for assistance. U.K. DI holders will be given advance notice if, in the future, the Company decides to discontinue and/or make any amendments to the existing U.K. DI arrangements. CSN Participants The Company's existing CSN arrangements will not be impacted by the London Delisting. Accordingly, following the London Delisting, CSN participants may continue to hold interests in Ordinary Shares through U.K. DIs via the CSN. However, following the London Delisting it will only be possible to place on market trades in respect of Ordinary Shares on Nasdaq. Consequently, when trading through a continuation of the existing service, CSN participants may be exposed to fluctuations in the exchange rate between U.S. dollars (being the currency in which Nasdaq trades are settled) and pounds sterling (being the default currency in which CSN participants will receive sale proceeds). Accordingly, CSN participants may consider taking one of the following actions in advance of the London Delisting. (1) If resident in the United Kingdom, Channel Islands, or Isle of Man, sell their interests in Ordinary Shares through the existing Internet Sale Dealing Service provided by Computershare U.K., with instructions to be submitted by no later than 4:30 p.m. (U.K. time) on July 21, 2025. If resident in a jurisdiction other than the United Kingdom, Channel Islands, or Isle of Man, sell via Computershare U.K.'s Postal Dealing Service, with instructions to be received by Computershare U.K. no later than 5:30 p.m. (U.K. time) on July 18, 2025. (2) Withdraw from the CSN facility and request Computershare U.K. to deliver their U.K. DIs to their nominated broker, custodian or nominee account in CREST, who may either: (i) reposition their interests in Ordinary Shares to a broker or custodian account in DTC; (ii) place a trade on the LSE prior to the London Delisting (as an alternative service to the trading services available through the CSN facility); or (iii) continue to hold their U.K. DIs pending future instructions (in which case they will be treated as other U.K. DI Holders – see section above). (3) Withdraw from the CSN facility and request Computershare U.K. to cancel the underlying U.K. DIs so as to receive their Ordinary Shares directly in certificated form on a share register administered in the U.S. Note: this could expose shareholders to a future U.K. Stamp Duty liability of 1.5% of the value of their Ordinary Shares when the shareholder subsequently decides to trade on Nasdaq. CSN participants will be given advance notice if, in the future, the Company decides to discontinue and/or make any amendments to the existing CSN arrangements. Appendix 2: Additional Details regarding the Code and the Panel The Code is issued and administered by the Panel. The Code currently applies to the Company and, accordingly, shareholders are entitled to the protections afforded by the Code. The Code and the Panel operate principally to ensure that shareholders in an offeree company are treated fairly and are not denied an opportunity to decide on the merits of a takeover and that shareholders in the offeree company of the same class are afforded equivalent treatment by an offeror. The Code also provides an orderly framework within which takeovers are conducted. In addition, it is designed to promote, in conjunction with other regulatory regimes, the integrity of the financial markets. The Code is based upon a number of General Principles, which are essentially statements of standards of commercial behavior. The General Principles apply to takeovers and other matters to which the Code applies. They are applied by the Panel in accordance with their spirit in order to achieve their underlying purpose. In addition to the General Principles, the Code contains a series of rules. Like the General Principles, the rules are to be interpreted to achieve their underlying purpose. Therefore, their spirit must be observed as well as their letter. The Panel may derogate or grant a waiver to a person from the application of a rule in certain circumstances. The following is a summary of key provisions of the Code which apply to transactions to which the Code applies. Equality of treatment General Principle 1 of the Code states that all holders of the securities of an offeree company of the same class must be afforded equivalent treatment. Furthermore, Rule 16.1 requires that, except with the consent of the Panel, special arrangements may not be made with certain shareholders in the offeree company if there are favorable conditions attached which are not being extended to all shareholders. Information to shareholders General Principle 2 requires that the holders of the securities of an offeree company must have sufficient time and information to enable them to reach a properly informed decision on the takeover bid. Consequently, a document setting out full details of an offer must be sent to the offeree company's shareholders. The opinion of the offeree board and independent advice The board of the offeree company is required by Rule 3.1 to obtain competent independent advice as to whether the financial terms of any offer are fair and reasonable and the substance of such advice must be made known to its shareholders. Rule 25.2 requires the board of the offeree company to send to shareholders and persons with information rights its opinion on the offer and its reasons for forming that opinion. That opinion must include the board's views on: (i) the effects of implementation of the offer on all the company's interests, including, specifically, employment; and (ii) the offeror's strategic plans for the offeree company and their likely repercussions on employment and the locations of the offeree company's places of business. The document sent to shareholders must also deal with other matters such as interests and recent dealings in the securities of the offeror and the offeree company by relevant parties and whether the directors of the offeree company intend to accept or reject the offer in respect of their own beneficial shareholdings. Rule 20.1 states that, except in certain circumstances, information and opinions relating to an offer or a party to an offer must be made equally available to all offeree company shareholders and persons with information rights as nearly as possible at the same time and in the same manner. Optionholders and holders of convertible securities or subscription rights Rule 15 provides that when an offer is made and the offeree company has convertible securities, options or subscription rights outstanding, the offeror must make an appropriate offer or proposal to the holders of those securities to ensure their interests are safeguarded. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE U.K. BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018) View original content to download multimedia: SOURCE Indivior PLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
27-05-2025
- Business
- Associated Press
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. 'Patrick is an accomplished and respected commercial leader whose strong track record driving growth in branded medicines make him an excellent addition to the executive team,' said Joe Ciaffoni, Chief Executive Officer. 'Patrick's breadth and depth of commercial experience will be instrumental in delivering on the Company's potential.' Barry has more than 30 years of commercial leadership experience in the pharmaceutical industry. He brings a track record of building and transforming high-performing commercial organizations to deliver sustained revenue growth across multiple product portfolios. Prior to joining Indivior, Barry served since 2020 as executive vice president and chief commercial officer for Endo Pharmaceuticals. In this role he led all commercial activities across three U.S. business segments, including branded pharmaceuticals and a Canadian affiliate with full responsibility for approximately $2 billion in revenue. 'I am honored to join Indivior at such a pivotal time for the company,' said Barry. 'Indivior has built a strong foundation and is well-positioned to broaden its leadership position in opioid use disorder. I look forward to working with the team to grow SUBLOCADE and maximize the potential of the Indivior portfolio.' Prior to Endo, Barry spent over two decades at Sanofi with increasing levels of responsibility over a range of senior leadership positions, spanning specialty pharmaceuticals, injectables, medical aesthetics, and branded medicines, with demonstrated success in turnaround scenarios, product launches, and market development. Barry holds an MBA from Cornell University and a bachelor's degree in public relations and marketing from McKendree University. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting View original content to download multimedia: SOURCE Indivior PLC
Yahoo
01-05-2025
- Health
- Yahoo
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During Pregnancy" in the American Journal on Addictions, evaluating the use of SUBLOCADE for the treatment of opioid use disorder (OUD) during pregnancy and postpartum. Three sources of data evaluated in this retrospective study illustrated that the use of monthly SUBLOCADE during pregnancy demonstrated no increased risk and is consistent with the established buprenorphine safety profile.1 This retrospective study includes clinical case studies from four pregnant patients treated with monthly SUBLOCADE, postmarketing surveillance data covering more than five years, and a targeted literature review. In total, 322 reports of pregnancy exposures to SUBLOCADE were identified. Of the four patients included in the clinical practice case studies, all delivered full-term infants with normal birthweight, no fetal anomalies, and no need for treatment for neonatal opioid withdrawal syndrome (NOWS). "The findings shared in this manuscript support perinatal, patient-centered decision-making," said Melinda Ramage, FNP-BC, CARN-AP, LCAS, Director of the North Carolina Perinatal Substance Use Disorder Network and lead author of the publication. "Treatment is not one-size-fits-all, and it is important to explore safe and effective options for the mother–baby dyad." Between 2010 and 2017, opioid use during pregnancy dramatically increased, with a 131% increase in opioid use-related diagnoses at delivery in the U.S.2 The U.S. national maternal morbidity and mortality data reveal mental health and substance use disorders are the leading underlying cause of pregnancy-related deaths in 36 states. While pregnancy-associated overdose deaths have been steadily rising since 2007, those involving fentanyl and other synthetic opioids markedly increased from 5.73 to 9.47 deaths per 100,000 in a span of just 3 years (2017–2020), with most deaths occurring post-delivery.3 This study helps address the current knowledge gap with relevant experience from patients and prescribers who used monthly SUBLOCADE during pregnancy and/or postpartum. In addition to the case studies, the postmarketing surveillance data showed live births with no reported birth defects in the majority of known cases and rates of spontaneous abortion and other outcomes consistent with or lower than general population rates. Review of relevant literature also aligned with the findings from postmarketing and clinical data sources. These data highlight buprenorphine's established safety profile and offers practical insights into clinical care. "OUD patients who are pregnant run the risk of experiencing a number of negative health consequences, such as infection, overdose, severe maternal morbidity, postpartum readmission, and even death, and using opioids during pregnancy has been linked to poor results for both the fetus and the newborn," said Christian Heidbreder, Chief Scientific Officer at Indivior. "As public health professionals and policymakers look for ways to reduce maternal overdose deaths, this study offers important new information about how long-acting medications like SUBLOCADE might be incorporated into a broader strategy to increase access and enhance outcomes for families affected by OUD." Treatment decisions during pregnancy and postpartum should reflect a shared decision-making approach between providers and patients, aligning with clinical guidance and product labeling. The patient-centered model is especially critical when managing chronic conditions, like OUD, in the perinatal period. These data support consideration of using SUBLOCADE as part of evidence-based treatment options, which include offering or continuing perinatal medications for OUD, prioritizing patient stability when considering a change of existing pharmacotherapy in pregnancy and postpartum, and assessing the benefits and risks in a patient-centered framework. This is the largest amount of data available regarding the experience of pregnant patients on SUBLOCADE. Limitations of the study include limited descriptive data for case studies obtained from a small patient cohort and 21% of pregnancies reported outcomes for postmarketing surveillance. Disclosure:This work was funded by Indivior Inc., with the exception of the case studies and the time and contributions of Melinda Ramage, which were not supported by Indivior. About SUBLOCADE®SUBLOCADE ® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATIONINDICATIONSUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATIONWARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONSHypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONSAddiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONSAdverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit About Opioid Use Disorder (OUD)Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions. About IndiviorIndivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting References: Ramage M, Bishop B, Mangano V, Mankabady B. Monthly Buprenorphine Depot Injection (SUBLOCADE®) for Opioid Use Disorder During Pregnancy. Am J Addict. 2025. Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010–2017. JAMA. 2021; 325(2): 146-155. doi:10.1001/jama.2020.24991 Bruzelius E, Martins SS. US trends in drug overdose mortality among pregnant and postpartum persons, 2017–2020. JAMA. 2022; 328(21): 2159-2161. doi:10.1001/jama.2022.17045 View original content to download multimedia: SOURCE Indivior PLC
Yahoo
24-04-2025
- Business
- Yahoo
Indivior Announces Q1 2025 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at The earnings release can be found at The investor presentation can be found at (at 7:00 am ET) There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: Participants may access the presentation telephonically by registering with the following link: will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting View original content to download multimedia: SOURCE Indivior PLC Sign in to access your portfolio
